Table 1.
Normal renal function(n =645) | Preoperative renal insufficiency(n =60 ) | p | |
---|---|---|---|
Male | 553 (85.7%) | 54 (90.0%) | 0.361 |
Age | 67 (58-73) | 69 (60-76) | 0.067 |
ORC | 451 (69.9%) | 41 (68.3%) | 0.798 |
LRC | 194 (30.1%) | 19 (31.7%) | |
BMI (kg/m2) | 23.9 (21.8-26.3) | 24.3 (22.2-26.0) | 0.443 |
ASA score | <0.001 | ||
≤2 | 552 (85.6%) | 398(63.3%) | |
>2 | 93(14.4%) | 22(36.7) | |
Type of urinary diversion | 0.014 | ||
Ureterocutaneostomy | 166 (25.7%) | 26 (43.3%) | |
Ileal conduit | 447 (69.3%) | 33 (55.0%) | |
Orthotopic neobladder | 32 (5%) | 1 (1.7%) | |
Time of operation (min) | 302 (230-374) | 269 (209-354) | 0.07 |
EBL (ml) | 500(200-1000) | 600 (200-1000) | 0.785 |
Clavien-Dindo class | 0.001 | ||
0 | 190 (29.5%) | 14(23.3%) | |
1 | 7(1.1%) | 0 | |
2 | 424 (65.7%) | 36 (60.0%) | |
3 | 17 (2.6%) | 4 (6.7%) | |
4 | 6 (0.9%) | 5 (8.3%) | |
5 | 1 (0.2%) | 1 (1.7%) | |
Major complication | 24 (3.7%) | 10 (16.7%) | <0.001 |
Postoperative stay (days) | 10 (8-14) | 11 (8-15) | 0.938 |
Clinical T stage | <0.001 | ||
Ta and Tis and T1 | 194 (30.1%) | 5 (8.3%) | |
T2 | 226(35.0%) | 16 (26.7%) | |
T3 | 142 (22.0%) | 20 (33.3%) | |
T4 | 83 (12.9%) | 19 (31.7%) | |
Pathological T stage | <0.001 | ||
Ta and Tis and T1 | 189 (29.3%) | 5 (8.3%) | |
T2 | 204 (31.6%) | 15 (25.0%) | |
T3 | 195(30.2%) | 30 (50.0%) | |
T4 | 57(8.8%) | 10 (16.7%) | |
Pathologic nodal stage | 0.027 | ||
N0 | 553(85.7%) | 45(75%) | |
N+ | 92(14.3%) | 15(25%) | |
Pathologic grade | 0.613 | ||
Low grade | 67 (10.4%) | 5 (8.3%) | |
High grade | 577 (89.6%) | 55 (91.7%) | |
Negative margin | 635 (98.4%) | 56(93.3%) | 0.026 |
Positive margin | 10 (1.6%) | 4 (6.7%) | |
Chemotherapy | 126 (19.5%) | 9 (15.0%) | 0.393 |
No chemotherapy | 519 (80.5%) | 51 (85.0%) |
ORC, open radical cystectomy; LRC , laparoscopic radical cystectomy; BMI, Body Mass Index; EBL, estimated blood loss; ASA, American Society of Anesthesiologists.